Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
XP-005 Personalized Vaccine in Acute Myeloid Leukemia: NCT06980155 Clinical Landscape Report 2026
15 October 2026
NCT06980155 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
OL-108 in Idiopathic Inflammatory Myopathies: NCT06980597 Clinical Landscape Report 2026
15 October 2026
NCT06980597 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Realgar-Indigo naturalis formula in Acute Promyelocytic Leukemia: NCT06982274 Clinical Landscape Report 2026
15 October 2026
NCT06982274 clinical landscape for Acute Promyelocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti CD19 chimeric antigen receptor T cell therapy(Beijing Boren Hospital) in Idiopathic Inflammatory Myopathies: NCT06983964 Clinical Landscape Report 2026
15 October 2026
NCT06983964 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Doxorubicin Hydrochloride liposomal in Locally Advanced Soft Tissue Sarcoma: NCT06981637 Clinical Landscape Report 2026
15 October 2026
NCT06981637 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fludarabine Phosphate in Plasma Cell Leukemia: NCT06986434 Clinical Landscape Report 2026
15 October 2026
NCT06986434 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RG-6540 in Lupus Nephritis: NCT06984341 Clinical Landscape Report 2026
15 October 2026
NCT06984341 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06990321 Clinical Landscape Report 2026
15 October 2026
NCT06990321 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT0596 CAR-T Cell in Plasma Cell Leukemia: NCT06988059 Clinical Landscape Report 2026
15 October 2026
NCT06988059 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib in Acute Myeloid Leukemia: NCT06987058 Clinical Landscape Report 2026
15 October 2026
NCT06987058 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rilvegostomig in Recurrent Endometrial Cancer: NCT06989112 Clinical Landscape Report 2026
15 October 2026
NCT06989112 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acasunlimab in Melanoma, Cutaneous Malignant: NCT06984328 Clinical Landscape Report 2026
15 October 2026
NCT06984328 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.